U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07393204) titled 'Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL' on Dec. 22, 2025.
Brief Summary: This study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy
Study Start Date: Dec. 10, 2025
Study Type: OBSERVATIONAL
Condition:
Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
Refractory Diffuse Large B-Cell Lymphoma
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Andres Jose Maria Ferreri
Information provided by (Responsible Party): Andres Jose Maria Ferreri, IRCCS San Raffaele
Disclaimer: Curated by HT Synd...